GambiaTuberculosis profile
Population  2014 1.9 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.35 (0.24–0.47) 18 (12–25)
Mortality (HIV+TB only) 0.14 (0.1–0.18) 7.2 (5.4–9.3)
Prevalence  (includes HIV+TB) 2.4 (1.8–3.1) 126 (95–160)
Incidence  (includes HIV+TB) 3.4 (2.8–4) 174 (145–206)
Incidence (HIV+TB only) 0.78 (0.64–0.93) 40 (33–48)
         
Case detection, all forms (%) 76 (64–91)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.48 (0.01–2.6) 0 (0–18)
MDR-TB cases among notified pulmonary
TB cases
11 (0–59) 0 (0–20)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 475   81
Pulmonary, clinically diagnosed 787   0
Extrapulmonary 209   0
       
Total new and relapse 2 552    
Previously treated, excluding relapses 31    
Total cases notified 2 583    
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 96 (86%) 96
Laboratory-confirmed RR-/MDR-TB cases     15
Patients started on MDR-TB treatment ***     9
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 169 (84)
HIV-positive TB patients 429 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 381 (89)
HIV-positive TB patients on antiretroviral therapy (ART) 205 (48)
HIV-positive people screened for TB 2 553  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (86) 1 431
Previously treated cases registered in 2013    
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.7
Culture (per 5 million population) 2.6
Drug susceptibility testing (per 5 million population) 2.6
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-01 Data: www.who.int/tb/data